

1. Willan, A. R., Lin, D. Y., Cook, R. J. and **Chen B. E.** (2002). Using inverse-weighting in cost-effectiveness analysis with censored data. *STATISTICAL METHODS IN MEDICAL RESEARCH*. **11**, 539-551.
2. **Chen, B. E.** and Cook, R. J. (2003). Regression Models for Point Processes with Interval Censored Covariates. *LIFETIME DATA ANALYSIS*. **9**, 291-307.
3. Willan, A. R., **Chen, B. E.**, Cook, R. J. and Lin, D. Y. (2003). Incremental net benefit in randomized clinical trials with quality-adjusted survival. *STATISTICS IN MEDICINE*. **22**, 353-362.
4. **Chen, B. E.** and Cook, R. J. (2004). Tests for Multivariate recurrent events in the presence of a terminal event. *BIOSTATISTICS*. **5**, 129-143.
5. **Chen, B. E.**, Cook, R. J., Lawless, J. F. and Zhan, M. (2005). Statistical methods for multivariate interval-censored recurrent events. *STATISTICS IN MEDICINE*. **24**, 671-691.
6. Kramer, J. L., Velazquez, I. A., **Chen, B. E.**, Rosenberg, P. S., Struewing, J. P., and Greene, M. H. (2005). Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. *JOURNAL OF CLINICAL ONCOLOGY*. **23**, 8629-8635.
7. **Chen, B. E.**, Sakoda, L. C., Hsing, A. W., and Rosenberg, P. S. (2006). Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. *GENETIC EPIDEMIOLOGY*. **30**, 495-507.
8. Anderson, W. F., **Chen, B. E.**, Jatoi, I., and Rosenberg, P. S. (2006). Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. *BREAST CANCER RESEARCH AND TREATMENT*. **100**, 121-126.
9. Rosenberg, P. S., Che, A., and **Chen, B. E.** (2006). Multiple hypothesis testing strategies for genetic case-control association studies. *STATISTICS IN MEDICINE*. **25**, 3134-3149.
10. Sakoda, L. C., Gao, Y. T., **Chen, B. E.**, Chen, J., Rosenberg, P. S., Rashid, A., Deng, J., Shen, M. C., Wang, B. S., Han, T. Q., Zhang, B. H., Cohen-Webb, H., Yeager, M., Welch, R., Chanock, S., Fraumeni, J. R. Jr., and Hsing, A. W. (2006). Prostaglandin-endoperoxide synthase 2 gene polymorphisms and risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. *CARCINOGENESIS*. **27**, 1251-1256.
11. Schairer, C., Brown, L. M., **Chen, B. E.**, Howard, R., Lynch, C. F., Hall, P., Storm, H., Pukkala, E., Andersen, A., Kaijser, M., Andersson, M., Joensuu, Hand., Fossa, S. D., Ganz, P. A., and Travis, L. B. (2006). Suicide after breast cancer: an international population-based study of 723,810 women. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. **98**, 1416-1419.
12. Goedert, J. J., **Chen, B. E.**, Preiss, L., Aledort, L. M., and Rosenberg, P. S. (2007). Reconstruction of hepatitis C virus in the U.S. hemophilia population, 1940 – 1990. *AMERICAN JOURNAL OF EPIDEMIOLOGY*. **165**, 1443-1453.
13. Hisada, M., **Chen, B. E.**, Jaffe, E. S., and Travis, L. B. (2007). Second cancer incidence and cause-specific mortality following hairy cell leukemia: a population-based study. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. **99**, 215-222.
14. Jatoi, I., **Chen, B. E.**, Anderson, W. F., and Rosenberg, P. S. (2007). Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. *JOURNAL OF CLINICAL ONCOLOGY*. **25**, 1683-1690.
15. Schairer, C., Hisada, M., **Chen, B. E.**, Brown, L. M., Howard, R., Fossa, S. D., Gail, M. H. and Travis, L. B. (2007). Comparative mortality for 621 second cancers in 29356 testicular

- cancer survivors and 12420 matched first cancers. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. **99**, 1248-1256.
16. Qu, C. X., Kamangar F., Fan, J. H., Yu, B., Sun, X. D., Taylor, P. R., **Chen, B. E.**, Abnet, C. C., Qiao, Y. L., Mark. S. D. and Dawsey, S. M. (2007). Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. **99**, 1240-1247.
 17. Chaturvedi, A. K., Engels, E. A., Gilbert, E. S., **Chen, B. E.**, Storm, H., Lynch, C.F., Hall, P., Langmark, F., Pukkala, E., Kaijser, M., Andersson, M., Fosså S. D., Joensuu, H., Boice, J. D., Kleinerman, R. A., Travis, L. B. (2007). Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. **99**, 1634-1243.
 18. Brown, L. M., **Chen, B. E.**, Pfeiffer, R., Schairer, C., Hall, P., Storm, H., Pukkala, E., Langmark, F., Kaijser, M., Andersson, M., Joensuu, H., Fossa, S. D. and Travis, L. B. (2007). Risk of second non-hematological malignancies among 376,825 breast cancer survivors. *BREAST CANCER RESEARCH AND TREATMENT*. **106**, 439-451.
 19. Anderson, W. F., **Chen, B. E.**, Brinton, L.A., and Devesa, S.S. (2007). Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers. *CANCER CAUSES AND CONTROL*. **18**, 1187-1198.
 20. Howard, R., Gilbert, E.S., **Chen, B. E.**, Hall, P., Storm, H., Pukkala, E., Langmark, F., Kaijser, M., Andersson, M., Joensuu, H., Fossa, S. D., and Travis, L. B. (2007). Leukemia following breast cancer: an international population-based study of 376,825 women. *BREAST CANCER RESEARCH AND TREATMENT*. **105**, 359-368.
 21. Anderson, W. F., Matsuno, R. K., Sherman, M. E., Lissowska, J., Gail, M. H., Brinton, L. A., Yang, X., Peplonska, B., **Chen, B. E.**, Rosenberg, P. S., Chatterjee, N., Szeszenia-Dabrowska, N., Bardin-Mikolajczak, A., Zatonski, W., Devesa, S. S., Garcia-Closas, M. (2007). Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. *CANCER CAUSES AND CONTROL*. **18**, 439-447.
 22. **Chen, B. E.**, Kramer, J. L., Greene, M. H., and Rosenberg, P. S. (2008). Competing risks analysis of correlated failure time data. *BIOMETRICS*. **64**, 172-179.
 23. Menashe, I., Rosenberg, P. S. and **Chen B. E.** (2008). PGA: power calculator for genetic association analyses. *BMC GENETICS*. **9**, 36.
 24. **Chen, B. E.**, Kramer, J. L., Greene, M. H., and Rosenberg, P. S. (2008). Rejoinder to Letter to the Editors on “Competing risks analysis of correlated failure time data”. *BIOMETRICS*. **64**, 1298-1298.
 25. Hsing, A. W., Sakoda, L. C., Rashid, A., Andreotti, G., Chen, J. Wang, B. S., Shen, M. C., **Chen, B. E.**, Rosenberg, P. S., Zhang, M., Niwa, S. Chu, L. Welch, R. Fraumeni, J. F., Gao, Y. T. and Chanock, S. (2008). Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. *CANCER RESEARCH*. **68**, 6442-6452.
 26. Andreotti, G., Chen, J., Gao, Y. T., Rashid, A., **Chen, B. E.**, Rosenberg, P. S., Sakoda, L. C., Deng, J., Shen, M. C., Wang, B. S., Han, T. Q., Zhang, B. H., Yeager, M., Welch, R., Chanock, S., Fraumeni, J. F. and Hsing, A. W. (2008). Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. *CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTATION*. **17**, 525-534.

27. Danforth, K. N., Rodriguez, C., Hayes, R. B., Sakoda, L. C., Huang, W. Y., Yu, K., Calle, E. E., Jacobs, E. J., **Chen, B. E.**, Andriole, G. L., Figueroa, J. D., Yeager, M., Platz, E. A., Michaud, D. S., Chanock, S. J., Thun, M. J. and Hsing, A. W. (2008). TNF polymorphisms and prostate cancer risk. *PROSTATE*. **68**, 400-407.
28. Danforth, K. N., Hayes, R. B., Rodriguez, C., Yu, K., Sakoda, L. C., Huang, W. Y., **Chen, B. E.**, Chen, J., Andriole, G. L., Calle, E. E., Jacobs, E. J., Chu, L. W., Figueroa, J. D., Yeager, M., Platz, E. A., Michaud, D. S., Chanock, S. J., Thun, M. J. and Hsing, A. W. (2008). Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. *CARCINOGENESIS*. **29**, 568-572.
29. Huang, W. Y., Gao, Y. T., Rashid, A., Sakoda, L. C., Deng, J., Shen, M. C., Wang, B. S., Han, T. Q., Zhang, B. H., **Chen, B. E.**, Rosenberg, P. S., Chanock, S., Hsing, A. W. (2008). Selected Base Excision Repair Gene Polymorphisms and Susceptibility to biliary tract cancer and biliary stones: A Population-Based Case-Control Study in China. *CARCINOGENESIS*. **29**, 100-105.
30. Chang, S. C., Rashid, A., Gao, Y. T., Andreotti, G. Shen, M. C., Wang, B. S., Han, T. Q., Zhang, B. H., Sakoda, L. C., Leitzmann, M. F., **Chen, B. E.**, Rosenberg, P. S., Chen, J., Chanock, S. J. and Hsing, A. W. (2008). Polymorphism of genes related to insulin sensitivity and the risk of biliary tract cancer and biliary stone: a population-based case-control study in Shanghai, China. *CARCINOGENESIS*. **29**, 944-948.
31. Chaturvedi, A. K., Engels, E. A., Gilbert, E. S., **Chen, B. E.**, Storm, H., Lynch, C.F., Hall, P., Langmark, F., Pukkala, E., Kaijser, M., Andersson, M., Fosså S. D., Joensuu, H., Boice, J. D., Kleinerman, R. A., Travis, L. B. (2007). Re: Second cancers among 104760 survivors of cervical cancer: Evaluation of long-term risk – Reply. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. **100**, 600-601.
32. **Chen, B. E.** and Cook, R. J. (2009). The analysis of multivariate recurrent events with partially missing event types. *LIFETIME DATA ANALYSIS*. **15**, 41-58.
33. Mai, P. L., **Chen B. E.**, Tucker, K., Friedlander, M., Phillips, K. A., Hogg, D., Jewett M. A., Bodrogi, I., Geczi, L., Olah, E., Heimdal, K., Fossa, S. D., Nathanson, K. L., Korde, L., Easton, D. F., Dudakia, D., Huddart, R., Stratton, M. R., Bishop, D. T., Rapley, E. A., Greene, M. H. (2009). Younger Age-at-Diagnosis for Familial Malignant Testicular Germ Cell Tumor. *FAMILIAL CANCER*. **8**, 451-456.
34. Shen, M., Chapman, R. S., Vermeulen, R., Tian, L., Zheng, T., **Chen, B. E.**, Engels, E. A., He, X., Blair, A., Lan, Q. (2009). Coal use, stove improvement, and adult pneumonia mortality in Xuanwei, China: a retrospective cohort study. *ENVIRONMENTAL HEALTH PERSPECTIVES*. **117**, 261-266.
35. Park, S. K., Andreotti, G., Sakoda, L. C., Gao, Y. T., Rashid, A., Chen, J., **Chen, B. E.**, Rosenberg, P. S., Shen, M. C., Wang, B. S., Han, T. Q., Zhang, B. H., Yeager, M., Chanock, S., Hsing, A. W. (2009). Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. *CARCINOGENESIS*. **30**, 606-614.
36. Wacholder, S., **Chen, B. E.** Wilcox, A., Macones, G., Gonzalez, P., Befano, B., Hildesheim, A., Rodríguez, A. C., Solomon, D., Herrero, R. and Schiffman, M. (2010). Risk of miscarriage in two randomized controlled trials of a bivalent vaccine against human papillomavirus types 16 and 18. *BRITISH MEDICAL JOURNAL*. **340**:c712.
37. Lee, K. M., Chapman, R. S., Shen, M., Lubin, J. H., Silverman, D. T., He, X., Hosgood, H. D. **Chen, B. E.**, Rajaraman, P., Caporaso, N. E., Fraumeni, JF Jr, Blair, A., Lan, Q. (2010).

- Differential effects of smoking on lung cancer mortality before and after household stove improvement in Xuanwei, China. *BRITISH JOURNAL OF CANCER*. **103**, 727-729.
38. **Chen, B. E.** Graubard, B., Flegal, K. M. and Gail, M. H. (2011). Comparing strategies to estimate the association of obesity with mortality via a Markov model. *STATISTICS AND ITS INTERFACE*. **4**, 451-462.
 39. Goodwin, P. J., Stambolic, V., Lemieux, J., **Chen, B. E.**, Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., Pritchard, K. I., Whelan, T. J. Rastogi, P. Shepherd, L. E. (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. *BREAST CANCER RESEARCH AND TREATMENT*. **126**, 215-220.
 40. Sehn, L. H., MacDonald, D., Rubin, S., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K., Gascoyne, R. D., Sussman, J., **Chen, B. E.**, Djurfeldt, M., Shepherd, L. E. (2011). Bortezomib Added to R-CVP (BR-CVP) is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group. *JOURNAL OF CLINICAL ONCOLOGY*. **25**, 3396-3401.
 41. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J.N., Horning, S. J., Dar, A. R., Shustik, C., Stewart, D. A., Crump, M., Djurfeldt, M. S., **Chen, B. E.**, Shepherd, L. E. (2012). ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. *NEW ENGLAND JOURNAL OF MEDICINE*. **366**, 399-408.
 42. Petrella, T., Tozer, R., Belanger, K., Savage, K. J., Wong, R., Kamel-Reid, K., Tron, V., **Chen, B. E.**, Hunder, N. N., Hagerman, L., Walsh, W., Eisenhauer, E. A. (2012). Interleukin-21 has activity in patients with metastatic melanoma: A phase II study. *JOURNAL OF CLINICAL ONCOLOGY*. **30**, 3396-3401.
 43. Jiang, W. and **Chen, B. E.** (2013). Estimating the prediction error in microarray classification: modifications on the .632+ bootstrap when $n < p$. *CANADIAN JOURNAL OF STATISTICS*. **41**, 133-150.
 44. Hay, A. E., Klimm, B., **Chen, B. E.**, Goergen, H., Shepherd, L. E., Fuchs, M., Gospodarowicz, M. K., Borchmann, P., Connors, J. M., Markova, J., Crump, M., Lohri, A., Winter, J.N., Dörken, B., Pearcey, R. G., Diehl, V., Horning, S. J., Eich, H. T., Engert, A., Meyer R. M. (2013). An individual patient-data comparison of Combined-Modality Therapy and ABVD alone for patients with limited-stage Hodgkin Lymphoma. *Annals of Oncology*. **24**, 3065-3069.
 45. Ramjeesingh, R., Meyer, R. M., Brouwers, M., **Chen, B. E.**, Booth, C. M. (2013). Alignment of practice guidelines with targeted therapy drug funding policies in Ontario. *Current Oncology*. **20**, 21-33.
 46. **Chen, B. E.**, Jiang, W. and Tu, D. (2014). Bayesian inference for treatment-biomarker interaction in clinical trials. *Computational Statistics and Data Analysis*. **71**, 324-334.
 47. *Wang, X., Lavigne, E., Ouellette-kuntz, H. and **Chen, B. E.** (2014). Acute impacts of extreme temperature exposure on emergency room admissions related to mental and behavior disorders in Toronto, Canada. *Journal of Affective Disorders*. **155**, 154-161.
 48. Chow, E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Brundage, M., Nabid, A., Tissing-Tan, C. J., Oei, B., Babington, S., Demas, W. F., Wilson, C. F., Meyer, R.M., **Chen, B. E.**, Wong, R. K. (2014). A Randomized Comparison of Single and Multiple Fractions of Repeat Radiation for Painful Bone Metastases. *Lancet Oncology*. **15**, 164-171.

49. Crump, M., Kuruvilla, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., Meyer R. M., Rubinger, M., Buckstein, R., Imrie, K. R., Federico, M., Renzo, N. D., Howson-Jan, K., Baetz, T., Kaizer, L., Voralia, M., Olney, H. J., Turner, A. R., Sussman, J., Hay, A. E., Djurfeldt, M. S., **Chen, B. E.** and Shepherd, L. E. (2014). A Randomized Comparison of Gemcitabine, Dexamethasone, Cisplatin and Dexamethasone, Cytarabine, Cisplatin Chemotherapy Prior to Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG Study LY.12. *Journal of Clinical Oncology*. **32**, 3290-3296.
50. Chow, E., Meyer, R. M., **Chen, B. E.**, van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Nabid, A., Tissing-Tan, C. J., Oei, B., Babington, S., Demas, W. F., Wilson, C. F., Wong, R. K. and Brundage, M. (2014). Impact of reirradiation of painful osseous metastases on Quality of Life and function: a secondary analysis of the NCIC CTG SC.20 randomized trial. *Journal of Clinical Oncology*. **32**, 3867-3873.
51. *Liu, Y., Jiang, W. and **Chen, B. E.** (2015). Testing for treatment-biomarker interaction based on local partial-likelihood. *Statistics in Medicine*. **34**, 3516-3530.
52. Mason, M. D., Parulekar, W. R., Sydes, M. R., Brundage, M., Kirkbride, P., Gospodarowicz, M., Cowan, R., Kostashuk, E. C., Anderson, J., Swanson, G., Parmar, M. K., Hayter C, Jovic G, Hiltz, A., Hetherington, J., Sathya, J., Barber, J. B., McKenzie, M., El-Sharkawi, S., Souhami, L., Hardman P. D., **Chen, B. E.**, Warde, P. (2015). Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. *Journal of Clinical Oncology*. **33**, 2143-2150.
53. Brundage, M. Sydes, M. R., Parulekar, W. R., Warde, P., Cowan, R., Bezjak, A., Kirkbride, P., Parliament, M., Moynihan, C., Bahary, J. P., Parmar, M. K., Sanders, K., **Chen, B. E.**, Mason, M. D., (2015). The impact of radiation therapy when added to androgen deprivation therapy for locally advanced prostate cancer: long-term Quality of Life outcomes from the NCIC CTG PR3/ MRC PR07 randomized trial. *Journal of Clinical Oncology*. **33**, 2151-2157.
54. Goodwin, P. J., Parulekar, W. R., Gelmon, K. A., Shepherd, L. E., Ligibel, J. A., Hershman, D. L., Rastogi, P., Mayer, I. A., Hobday, T. J., Lemieux, J., Thompson, A. M., Pritchard, K. I., Whelan, T. J., Mukherjee, S. D., Chalhchal, H. I., Oja, C. D., Tonkin, K. S., Bernstein, V., **Chen, B. E.**, Stambolic, V. (2015). Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early stage breast cancer. *Journal of the National Cancer Institute*. **103** (3).
55. Cheung, M. C. Hay, A. E., Crump, M., Imrie, K. R., *Song, Y., Hassan, S., Risebrough, N., Sussman, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., Baetz, T., Sz wajcer, D., Desjardins, P., Shepherd, L. E., Meyer R. M., R., Le, A., **Chen, B. E.**, Mittmann, N. (2015). A cost-utility analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, dexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin lymphoma. *Journal of the National Cancer Institute*. **107**, (7).
56. Kuruvilla, J., MacDonald, D. A., Kouroukis, C. T., Cheung, M., Olney, H. J., Turner, A. R., Anglin, P., Seftel, M., Ismail, W.S., Luminari, S., Couban, S., Baetz, T., Meyer, R. M., Hay A. E., Shepherd, L., Djurfeldt, M. S., Alamoudi, S., **Chen, B. E.**, Crump, M. (2015).

- Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. *Blood*. **126**, 733-738.
57. Cuffe S., Hon H., Tobros, K., Espin-Garcia, O., *Brhane, Y., Harland, L., Fadhel, E., Eng, L., LaDelfa, A., Waldron, J., Siu, L. L., **Chen, B. E.**, Xu, W., Simmons, C., Kassam, Z., Montenegro, A., Parulekar, W. R., Liu, G. (2015). Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial. *Clinical Trials*. **12**. 237-245.
 58. Whelan, T. J., Olivotto, I. A., Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman, J. A., **Chen, B. E.**, Levine, M. N. (2015). Regional Nodal Irradiation in Early-Stage Breast Cancer. *New England Journal of Medicine*. **373**, 307-316.
 59. Chow, E, DeAngelis C, **Chen, B. E.**, Azad A, Meyer RM, Wilson C, Kerba M, Bezjak A, Wilson, P., Nabid, A., Greenland J, Rees G, Vieth, R., Wong, R. K., Hoskin, P. (2015). Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U). *Radiotherapy Oncology*. **115**, 141-148.
 60. Monzon, J. G., Hay, A. E., McDonald, G. T., Pater, J. L., Meyer, R. M., Chen, E., **Chen, B. E.**, Dancey, J. E. (2015). Correlation of single arm versus randomised phase II oncology trial characteristics with phase III outcome. *European Journal of Cancer*. **17**, 2501-2507.
 61. Bartlett, J. M., Nielsen, T., Gao, D., Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, **Chen, B. E.**, Shepherd LE, Chapman, J. W. (2015). TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial. *British Journal of Cancer*. **113**, 722-728.
 62. Jiang, W., Moon, N. C., **Chen, B. E.**, and Tu, D. (2016). Permutation methods for comparing the accuracy of nested prediction models in survival analysis. *Communications in Statistics - Simulation and Computation*. **45**, 2691-2708.
 63. *Djrboua, M., **Chen, B. E.** and Davison, C. M. (2016). Physical fighting, fighting-related injuries and family affluence among Canadian youth. *BioMed Central (BMC) Public Health*. **16**. 199.
 64. Jiang, S., **Chen, B. E.**, Tu, D. (2016). Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. *Statistics in Medicine*. **35**, 2715-2725.
 65. *Djrboua, M., **Chen, B. E.** and Davison, C. M. (2016). Trends and demographic characteristics of physical fighting and fighting-related injuries among Canadian youth from 1993-2010. *Canadian Journal of Public Health*. **107**, 231-238.
 66. Cuffe, S., Azad, A. K., Qiu, X., Brhane, Y., Kuang, Q., Marsh, S., Savas, S., Chen, Z., Cheng, D., Leighl, N. B., Goss, G., Laurie, S.A., Seymour, L., Bradbury, P. A., Shepherd, F. A., Tsao, M. S. , **Chen, B. E.**, Xu, W., Liu, G. (2016). ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. *Cancer Epidemiology*. **41**, 50-56.
 67. Weberpals, J. I., Amin, M. S., **Chen, B. E.**, Tu, D., Spaans, J. N., Squire, J. A., Eisenhauer, E. A., Virk, S., *Ma, D., Duciaume, M., Hoskins, P., LeBrun, D. P. (2016). First application of the automated quantitative analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16. *Gynecology Oncology*. **140**, 486-493.

68. *Kim, C., *Seow, W. J., Shu, X., Bassig, B. A. Rothman, N., **Chen, B. E.**, Xiang, Y., Hosgood, H. D., Ji, B., Hu, W., Wen, C., Chow, W., Cai, Q., Yang, G., Gao, Y. T., Zheng, W., Lan, Q. (2016). Cooking coal use and all-cause and cause-specific mortality in a prospective cohort study of women in Shanghai, China. *Environmental Health Perspectives*. **124**, 1384-1389.
69. Spears, M., Lyttle, N., D'Costa, A., **Chen, B. E.**, Yao, C. Q., Boutros, P. C., Burnell, M., Levine, M.N., O'Brien, P., Shepherd, L., Bartlett, J. M. (2016). A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. *Oncotarget*. **7**, 49099-49106.
70. Baetz, T., **Chen, B. E.**, Couban, S., Kouroukis, C., Buckstein, R., Kuruvilla, J., Howson-Jan, K., Szwajcer, D., Federico, M., Meyer, R. M., Djurfeldt, M. S., Hay, A. E., Shepherd, L., Crump, M. (2016). Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12. *Leukemia Lymphoma*. **58**, 64-69.
71. Ingle, J. N., Xie, F., Ellis, M. J., Goss, P. E., Shepherd, L. E., Chapman, J. W., **Chen, B. E.**, Kubo, M., Furukawa, Y., Momozawa, Y., Stearns, V., Pritchard, K. I., Barman, P., Carlson, E. E., Goetz, M. P., Weinshilboum, R. M., Kalari, K. R., Wang, L. (2016). Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. *Cancer Research*. **76**, 7012-7023.
72. *Han, M., Murugesan, A., Bahlis, N. J., Song, K., White, D., Chen, C., Seftel, M. D., Howsen-Jan, K., Reece, D., Stewart, K., Xie, Y., Hay, A. E., Shepherd, L., Djurfeldt, M., Zhu, L., Meyer, R. M., **Chen, B. E.**, Reiman, T. (2016). A pharmaco-genetic analysis of the Canadian Cancer Trials Group MY10 clinical trial of maintenance therapy for multiple myeloma. *Blood*. **128**. 732-735.
73. South, A., Parulekar, W. R., Sydes, M. R., **Chen, B. E.**, Parmar, M. K., Clarke, N., Warde, P., Mason, M. (2016). Estimating the impact of randomised control trial results on clinical practice: Results from a survey and modelling study of androgen deprivation therapy plus radiotherapy for locally advanced prostate cancer. *European Urology Focus*. **3**. 276-283.
74. *Fang, T., Mackillop, W., Jiang, W., Hildesheim, A., Wacholder, S. and **Chen, B. E.** (2017). A Bayesian model for estimating a risk window: methods and application. *Computational Statistics and Data Analysis*. **112**, 53-62.
75. *Lin, L. A., Luo, S., **Chen, B. E.** and Davis, B. R. (2017). Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions. *Statistical Methods in Medical Research*. **26**, 2869-2884.
76. Siu, L. L., Waldron, J. N., **Chen, B. E.**, Winquist, E., Wright, J. R., Nabid, A., Hay, J. H., Ringash, J., Liu, G., Johnson, A., Shenouda, G., Chasen, M., Pearce, A., Butler, J. B., Breen, S., Chen, E. X., FitzGerald, T. J., Childs, T. J., Montenegro, A., O'Sullivan, B., Parulekar, W. R. (2017). Effect of standard radiotherapy with Cisplatin vs accelerated radiotherapy with Panitumumab in locoregionally advanced squamous cell Head and Neck Carcinoma: A randomized clinical trial. *JAMA Oncology*, **3**, 220-226.
77. **Chen, B. E.**, Siu, L. and Parulekar, W. R. (2017). How to demonstrate noninferiority of accelerated radiotherapy with Panitumumab to standard radiotherapy with Cisplatin in locoregionally advanced squamous cell head and neck carcinoma - Reply. *JAMA Oncology*. **3**, 1431.

78. Liu, S., **Chen, B. E.**, Burugu, S., Leung, S., Gao, D., Virk S, Kos, Z., Parulekar, W. R., Shepherd, L., Gelmon, K. A., Nielsen, T. O. (2017). Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic HER2-positive breast cancer: A secondary analysis of a randomized clinical trial. *JAMA Oncology*. **3**, 1-8.
79. Ringash, J., Waldron, J. N., Siu, L. L., Martino, R., Winquist, E., Wright, J. R., Nabid, A., Hay, J. H., Hammond, A., Sultanem, K., Hotte, S., Leong, C., El-Gayed AA, Naz F, Ramchandrar K, Owen, T. E., Montenegro, A., O'Sullivan, B., **Chen, B. E.**, Parulekar, W. R. (2017). Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). *European Journal of Cancer*, **72**, 192-199.
80. Skamene, T., Crump, M., Kerry, Savage, K. J., Reiman, T., Kuruvilla, J., Good, D., LeBrun, D., Meyer, R. M., Sehn, L. H., Soulières, D., Stakiw, J., Laferriere, N., Luminari, S., Shepherd, L. E., Djurfeldt, M., Zhu, L., **Chen, B. E.** and Hay, A. (2017). Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase III study. *Leukemia and Lymphoma*. **58**, 2319-2327.
81. Davison, K., **Chen, B. E.**, Kukreti, V., Couban, S., Bengner, A., Berinstein N, Kaizer, L., Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay, A. E., Shepherd, L., Crump, M. (2017). Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the Phase III CCTG LY.12 Trial. *Annals of Oncology*, **28**, 622-627.
82. Lohmann, A. E., Liebman, M. F., Brien, W., Parulekar, W. R., Gelmon, K. A., Shepherd, L. E., Ligibel, J. A., Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic, V., **Chen, B. E.**, Goodwin P. J. (2017). Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. *Breast Cancer Research and Treatment*. **164**, 317-378.
83. Liu, G., Cuffe, S., Liang, S., Azad, A. K., Cheng, L., *Brhane, Y., Qiu, X., Cescon, D. W., Bruce, J. P., Chen, Z., Cheng, D., Patel, D., Tse, B. C., Laurie, S. A., Goss, G. D., Leighl, N. B., Hung, R. J., Bradbury, P. A., Seymour, L., Shepherd, F. A., Tsao, M. S., **Chen, B. E.**, Xu, W., Reisman, D. N. (2017). BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial. *Clinical Cancer Research*. **23**, 2460-2470.
84. Pan, H, Gray, R., *et al* for Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2017). 20-year risks of Breast-Cancer recurrence after stopping endocrine therapy at 5 years. *New England Journal of Medicine*. **377**, 1836-1846.
85. *Gavanji, P., **Chen, B. E.** and Jiang, W. (2018). Residual Bootstrap for a threshold model in clinical trials with survival outcomes. *Statistics in Biosciences*. **10**, 202-216.
86. Leung, A. K., Puri, G., **Chen, B. E.**, *Gong, Z., Chan, E., Feng, E., Duic, M. (2018). Impact of physician navigators on productivity indicators in the emergency department. *Emergency Medicine Journal*, **35**, 5-11.
87. Bosch, M., Akhter, A., **Chen, B. E.**, Mansoor, A., Lebrun, D., Good, D., Crump, M., Shepherd, L. E., Scott, D. W., Steward, D. A., (2018). A bio-clinical prognostic model

- using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. *Haematologica*. **103**, 288-296.
88. Niravath, P. A., **Chen, B. E.**, Chapman, J. W., Agarwal, S.K., Welschhans, R. L., Bongartz, T., Kalari, K. R., Shepherd, L. E., Bartlett, J., Pritchard, K., Gelmon, K., Hilsenbeck, S. G., Rimawi, M. F., Osborne, C. K., Goss, P. E., Ingle, J. N. (2018). Vitamin D levels, vitamin D receptor polymorphisms, and inflammatory cytokines in aromatase inhibitor-induced arthralgias: An analysis of CCTG MA.27. *Clinical Breast Cancer*. **18**, 78-87.
 89. Strasser-Weippl, K., Sudan, G., Ramjeesingh, R., Shepherd, L. E., O'Shaughnessy, J. Parulekar, W. R., Liedke, P. E., **Chen, B. E.**, Goss, P. E. (2018). Outcomes in Women with Invasive Ductal or Invasive Lobular Early Stage Breast Cancer treated with Anastrozole or Exemestane in CCTG MA.27. *European Journal of Cancer*. **90**, 19-25.
 90. Reiman, T., Crump, M., Cheung, M., Shepherd, L., et al, **Chen, B. E.**, Hay, A. (2019). A phase I study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin combination therapy in the treatment of peripheral T-Cell and diffuse large B-Cell lymphoma; the Canadian Cancer Trials Group LY.15 study. *Leukemia and Lymphoma*. **60**, 912-919.
 91. Gray, R. et al for Early Breast Cancer Trailists' Collaborative Group (EBCTCG). (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet*, **33**, 1440-1452.
 92. Gross, J.P., Whelan, T. J., Parulekar, W. R., **Chen, B. E.**, Rademaker, A. W., Helenowski, I. B., Donnelly, E. D. and Strauss, J. B. (2019). Development and validation of a nomogram to predict lymphedema following axillary surgery and radiotherapy in women with breast cancer from the NCIC CTG MA.20 randomized trial. *International Journal of Radiation Oncology Biology Physics*, **105**, 165-173.
 93. Cheung, W.Y., Kornelsen, E.A., Mittmann, N., Leighl, N.B., Cheung, M., Chan, K.K., Bradbury, P.A., Ng, R.C.H., **Chen, B.E.**, Ding, K., Pater, J.L., Tu, D., and Hay, A.E. (2019). The economic impact of the transition from branded to generic oncology drugs. *Current Oncology*. **26**, 89-93.
 94. Hoch, J., Hay, A., Isaranuwatthai, W., Thavorn, K., Leighl, N. B., Tu, D., Trenman, L., Dewa, C. S., O'Callaghan, C., Patter, J., Jonker, D., **Chen, B. E.**, Mittmann, N. (2019). Advantages of net benefit regression for trial-based economic evaluations: An example from the Canadian Cancer Trials Group CO.17 trial. *BMC Cancer*. **19**, 552.
 95. Ingle, J. Kalari, K. R., Momozawa, Y., Kubo, M., Furukawa, Y., Shepherd, L. E., et al, Goetz, M. P., **Chen, B. E.**, Cairns, J. Weinshilboum, R., M., Wang L. (2019). Deep sequencing across germline GWAS signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. *Pharmacogenetics and Genomics*. **29**, 183-191.
 96. **Chen, B. E.** and *Wang, J. (2020). Joint Modeling of binary response and survival for clustered data in clinical trials. *Statistics in Medicine*, **39**, 326-339.
 97. Tan, X., **Chen, B. E.**, Sun, J. and Ibrahim, J. G. (2020). A hierarchical testing approach for detecting safety signals in clinical trials. *Statistics in Medicine*, **39**, 1541-1557.
 98. *Liu, S. and **Chen, B. E.** (2020). Continuous threshold models with two-way interaction in survival analysis. *Canadian Journal of Statistics*. **48**, 751-772.
 99. Bassig, B. A., Hosgood, D., Shu, X. Vermeulen, R., **Chen, B. E.**, Katki, H. A., Seow, W. J., Hu, W., Portengen, L., Ji, B., Wong, J., Ning, B., Downward, G., Li, J., Yang, K., Yang, G., Gao, Y. T., Xiang, Y., Nagaradona, T., Zheng, W., Silverman, D., Huang, Y. and Lan, Q.

- (2020). Ischemic heart disease and stroke mortality by specific coal type among non-smoking women with substantial indoor air pollution exposure in China. *International Journal of Epidemiology*. **49**, 56-68.
100. Ingle, J. N., Cairns, J., Suman, V. J., Shepherd, L. E., Fasching, P. A., et al, Kalari, K., R., Ellis, M. J., Goss, P. E., **Chen, B. E.**, Volz, B. et al, Wang, L. (2020). Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α . *Clinical Cancer Research*, **26**, 2986-2996.
 101. Chen, L., Tyryskin, K., Moore, A., Scott, D. W., Steidl, C., Li, Y., Shepherd, L. E., Rauh, M., Deng, L., Good, D., Virk, S., **Chen, B. E.**, Crocker, S., Baetz, T., LeBrun, D. P. (2020). Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and BCL2 gene alterations. *Leukemia and Lymphoma*. **61**, 1334-1344.
 102. Assouline, S., Amrein, L., Aloyz, R., Banerji, V., Caplan, S., Owen, C., Hasegawa, W., Robinson, S., Shivakumar, S., Prica, A., Peters, A., Hagerman, L., Rodriguez, L., Skamene, T., Panasci, L., **Chen, B. E.**, Hay, A. E. (2020), IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. *Leukemia and Lymphoma*. **61**, 1653-1659.
 103. Assouline, S., Li, S. Gisselbrecht, C., Fogarty, P., Hay, A., Shepherd, L. E., Schmitz, N., Baetz, T., Keating, A., Sue, R., Seftel, M., Djurfeldt, M., Meyer, R., Chen, B. E. and Crump, M. (2020). The conditional survival of patients with relapsed DLBCL after auto-transplant: A subgroup analysis of LY.12 and CORAL. *Blood Advances*. **4**, 2011-2017.
 104. Moku, P., Shepherd, L. E., Ali, S. M., Leitzel, K., Parulekar, W. R., Zhu, L., Virk, S., Nomikos, D., Aparicio, S., Gelmon, K. A., Drabick, J. J., Polimera, H. V., Pancholy, N., Spiegel, H., **Chen, B. E.**, Lipton, A. (2020). Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase III CCTG MA.31 trial. *Cancer*. **126**, 4859-4866.
 105. Dent, S., Botros, J, Rushton, M., Aseyev, O., Levine, M. N., Parulkear, W, R., O'Brien, P., Burnelle, M., Pritchard, K., **Chen, B. E.**, Shepherd, L. E. (2020). Anthracycline-Induced Cardiotoxicity in Patients with Early Stage Breast Cancer: The Canadian Cancer Trials Group (CCTG) MA.21. Experience. *Breast Cancer Research and Treatment*. **184**, 733-741.
 106. Rodriguez, L., Meyer, R. Pater, J. L., Zhang, S., Liu, H., Mulroy, L., Shepherd, L., Djurfeldt, M., **Chen, B. E.**, Hay, A. (2020). Comparison of Outcomes by Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD alone, a secondary analysis of the Canadian Cancer Trials Group HD.6 Trial. Manuscript submitted to *British Journal of Haematology*.
 107. Joy, A. A., Gelmon, K. A., Mates, M., Desbien, C., Clemons, M., Taylor, S., Lemieux, J., Bartlett, J., Chad, W., Koehler, M., *Liu, S., **Chen, B. E.** and Parulekar, W. R. (2020). Randomized phase II study comparing standard versus continuous dosing of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, human epidermal growth factor receptor 2 negative, advanced breast cancer. Manuscript submitted to *Journal of Clinical Oncology*.
 108. Petrella, T. M., Mihalciou, C., Monzon, J. et al, Spatz, A., Hagerman, L., **Chen, B. E.**, Dancey, J. (2020). Final Efficacy Results of CCTG IND.202: A randomized phase II study of recombinant Interleukin-21 (rIL-21) compared to Dacarbazine (DTIC) in patients

- with recurrent or metastatic melanoma (MM). *Cancer Immunology, Immunotherapy*. Submitted.
109. Venner, C. P., LeBlanc, R., Sandhu, I., White, D., Belch, AR, Reece, DE, Chen, C., Dolan, S., Lalancette, M., Louzada, M., Kew, A., McCurdy, A., Monteith, B., Reiman, T., McDonald, G., Sherry, M., Gul, E., **Chen, B. E.** and Hey, A. E. (2020). Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial. *American Journal of Hematology*, **96**, 552-560.
 110. Pimentel, I., **Chen, B. E.**, Lohmann, A. E., Ennis, M., Ligibel, J., Shepherd, L., Hershman, D. L., Whelan, T., Stambolic, V., Mayer, I., Hobday, T., Lemieux, J., Thompson, A., Rastogi, P., Gelmon, K., Rea, D., et al., Parulekar, W. R., Goodwin, P. (2021). The effect of metformin vs placebo on sex hormones in CCTG MA.32. *Journal of the National Cancer Institute*. **113**, 192-198.
 111. Hey, A. E., Mittmann, N., Crump, M., Cheung, M. C., Sleeth, J., Needham, J., Broekhoven, M., Djurfeldt, M., Shepherd, L. E., Meyer, R. M., **Chen, B. E.** and Pater, J. L. (2021). A Canadian prospective study of linkage of randomized clinical trial to cancer and mortality registry data. *Current Oncology*. **28**, 1153-1160.
 112. Prica, A., Hey, A. E., Crump, M., Mittmann, N., Shepherd, L. E., Meyer, R. M., Imrie, K. I., Risebrough, N., Djurfeldt, M., **Chen, B. E.** and Cheung, M. (2021). Evaluating the indirect costs of care associated with salvage chemotherapy for relapsed and refractory aggressive-histology lymphoma: A subset analysis of the Canadian Cancer Trials Group (CCTG) LY.12 clinical trial. *Current Oncology*. **28**, 1256-1261.
 113. Cheung, M., Chan, K., *Shane, G., Hay, A. E., Pater, J. L., Prica, A., **Chen, B. E.**, Leighl, N., Mittmann, N. (2021). Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. *Clinical Trials*. **18**, 500-504.
 114. Monteith, B., Venner, C., Cheung, M., Pater, J. L., Shepherd, L. E., Richardson, H., Reece, D., Gul, E., Lalancette, M., Castonguay, V., Kukreti, V., Tiedemann, R., Phua, C., Bhella, S., Dubebout, J., Sherry, M., *Yen, H., **Chen, B. E.** and Hey, A. E. (2021). A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. *European Journal of Haematology*. **107**, 333-342.
 115. Goodwin, P. J., Dowling, R. J. O., Ennis, M., **Chen, B. E.**, Parulekar, W. R., Shepherd, L. E., Burnell, M. J., Vander Meer, R., Molckovsky, A., Gurjal, A., Gelmon, K. A., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Whelan, T. J., Hobday, T. J., Rastogi, P., Rabaglio-Poretti, M., Lemieux, J., Thompson, A. M., Rea, D. W. and Stambolic, V. (2021). Effect of Metformin versus Placebo on metabolic factors in the CCTG MA.32 randomized breast cancer trials. *Nature publication journals: Breast Cancer*. **7**(1), 74.
 116. Del Paggio, J. C., Fundytus, A. M., Hopman, W. M., Pater, J. L., **Chen, B. E.**, Brundage, M. D., Hay, A. E. and Booth, C. M. (2021). Application of value frameworks to the design of clinical trials: the Canadian Cancer Trials Group experience. *Journal of the National Cancer Institute*. **113**, 1422-1428.
 117. Goodwin, P. J., Dowling, R. J. O., Ennis, M., Chen, B. E., Parulekar, W. R., Shepherd, L. E., Gelmon, K. A., Whelan, T. J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Rastogi, P., Rabaglio-Poretti, M., Lemieux, J., Thompson, A. M., Rea, D. W. and, Stambolic, V. (2021). Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A

- Breast Cancer Randomized Trial of Metformin vs Placeb. *Journal of National Cancer Institute, Cancer Spectrum*. **28**, 5(5): pkab066.
118. Cheung, M. C., Mittmann, N., Owen, C., Abdel-Samad, N., Fraser, G. A. M., Lam, S., Crump, M., Sperlich, C., van der Jagt, R., Prica, A., Couban, S., Woyach, J. A., Ruppert, A. S., Booth, A. M., Mandrekar, S. J., McDonald, G., Shepherd, L. E., *Yen, H., **Chen, B. E.** and Hey, A. E. (2021). A Prospective Economic Analysis of Alliance A041202/ CCTG CLC.2: A randomized phase III comparison of bendamustine-rituximab versus ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia. *Clinical Lymphoma Myeloma Leukemia*. **21**, 766-774.
 119. *Gavanji, P., Jiang, W., and **Chen, B. E.** (2022). Penalized likelihood ratio test in a mixture of regression models for biomarker cut-point detection in clinical trials. *Canadian Journal of Statistics*. **50**, 1-12.
 120. Goodwin, P. J., **Chen, B. E.**, Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., Rea, D. W., Stos, P. M., Shepherd, L. E., Stambolic, V., and Parulekar, W. R. (2022). Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. *Journal of American Medical Association*. **327**, 1963-1973.
 121. Zhang, X., Ritonja, J. A., Zhou, N., **Chen, B. E.** and Li, X. (2022). Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A dose-response meta-analysis of randomized controlled trials. *Journal of American Heart Association*. **11**, 1-44.
 122. Guan, Z., Webber, C., Flemming, J. A., Mavor, M. E., Whitehead, M., **Chen, B. E.** and Groome, P. A. (2022). Real-world colorectal cancer diagnostic pathways in Ontario, Canada: A population-based study. *European Journal of Cancer Care (English)*. **31**(5): e13603.
 123. Lohmann, A., Ennis, M., Parulekar, W. R., **Chen, B. E.**, Tomlinson, G., Goodwin, P. J. (2022). The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor-Positive Breast Cancer. *Journal of National Cancer Institute*. **114**, 924-929.
 124. Hilton, J., Gelmon, K., Bedard, P. L., Tu, D., Xu, H., Tinker, A. V., Goodwin, R., Laurie, S. A., Jonker, D., Hansen, A. R., Veitch, Z. W., Renouf, D. J., Hagerman, L., Lui, H., Chen, B. E., Kellar, D., Li, I., Lee, S. E., Kono, T., Cheng, BYC, Yap, D., Lai, D., Beatty, S., Soong, J., Pritchard, K. I., Soria-Bretones, I., Chen, E., Feilotter H, Rushton M, Seymour, L., Aparicio, S. and Cescon, D. W. (2022). Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. *Nature Communication*. **13**(1):3607.
 125. *Teng, W., Jiang, W. and **Chen, B. E.** (2023). A non-parametric simultaneous confidence band for biomarker effect on the restricted mean survival time. *Statistics in Medicine*. **42**, 297-315.
 126. *Everest, L. **Chen, B. E.**, Hey, A. E., Cheung, M. C. and Chan, K. W. (2023). Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group. *BMC Medical Research Methodology*. **23** (179), 1-11.
 127. Wang, T., Zhang, X., Zhou, N., Shen, Y., Li, B., **Chen, B. E.** and Li, X. (2023). Association between omega-3 fatty acid Intake and dyslipidemia: a continuous dose-

- response meta-analysis of randomized controlled trials. *Journal of American Heart Association*. **12** (e029512), 1-54.
128. Gupta, A., Hay A. E., Crump, M., Djurfeldt, M. S., Zhu, L., Cheung, M. C., Shepherd, L. E., **Chen, B. E.** and Booth, C. M. (2023). Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial. *Oncologist*. E-published.
 129. Hershman, D. L., **Chen, B. E.**, Sathe, C., Parulekar, W. R., Lemieux, J., Ligibel, J. A., Gelmon, K. A., Whelan, T. J., Goodwin, P. J. (2023). Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). *Breast Cancer Research and Treatment*. **200**, 93-102.

Note: An asterisk () is used to identify students who are co-authors in publication.*

BOOK CHAPTERS

1. Cook, R. J., **Chen, B. E.** and Major, P. (2004). Marginal analysis of point processes with competing risks. *HANDBOOK OF STATISTICS*. (Edited by N. Balakrishnan, and C. R. Rao). Vol. **23**. 349-361.
2. Anderson, W. F., Schairer, C., **Chen, B. E.**, Hance, K. W., and Levine, P. H. (2005). Epidemiology of inflammatory breast cancer (IBC). *BREAST DISEASE*. Vol. **22**. 9-23.
3. **Chen, B. E.**, Urton, A., Sadura, A. and Parulekar, W. R. (2020). Principles of protocol development. In: *Principles and Practice of Clinical Trials*. Edited by Piantadosi, S. and Meinert, C. L. Springer. Cham.